Investigating renal tissue responses to radiopharmaceutical therapy using multiparametric MRI
Authors:
Preprint
- 14 October 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Objectives Renal toxicity is a recognized potential adverse effect of radiopharmaceutical therapy (RPT). While 177 Lu-based therapies are generally well tolerated, subtle therapy-related renal changes remain insufficiently characterized. This study investigated longitudinal renal alterations during 177 Lu-based RPT using multiparametric magnetic resonance imaging (mpMRI) and evaluated its potential for renal monitoring. Methods Twenty-three patients undergoing RPT with either [ 177 Lu]Lu-DOTATATE (n = 14) or [ 177 Lu]Lu-PSMA (n = 9) underwent renal mpMRI examinations before and during therapy with up to four treatment cycles. Imaging included arterial spin labeling, diffusion-weighted imaging with intravoxel incoherent motion analysis, blood oxygenation level-dependent imaging, T1 mapping, and volumetry. Renal scintigraphy, estimated glomerular filtration rate (eGFR), and absorbed renal radiation dose were assessed longitudinally. Results No significant decline in eGFR was observed during RPT after exclusion of two patients who developed urinary tract obstruction (p = 0.19). Longitudinal analysis revealed significant temporal changes in T1 values (p = 0.008) and perfusion fraction of IVIM (p = 0.005), as well as a modest decrease in the corticomedullary BOLD ratio (p = 0.020). No significant longitudinal changes were detected for other MRI or scintigraphic parameters. Absorbed renal radiation dose was not associated with changes in MRI-derived biomarkers, eGFR, or renal scintigraphy (all p > 0.05). Patients with urinary obstruction demonstrated distinct MRI abnormalities, including reduced renal blood flow (RBF) and altered BOLD metrics. Conclusions No clinically relevant renal functional deterioration or major imaging abnormalities were detected during contemporary 177 Lu-based RPT. Subtle longitudinal T1 increases may reflect mild structural tissue remodeling without measurable functional consequences. Renal mpMRI is feasible for non-invasive monitoring and may provide complementary information beyond conventional renal function assessment. Trial registration, DRKS, DRKS00018966, registered 10 October 2019; https://www.drks.de/search/de/resultsKeywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Automated Coregistered Segmentation for Volumetric Analysis of Multiparametric Renal MRIMagnetic Resonance in Medicine, 2026
- Multiparametric MRI for Predicting Renal Function Deterioration and Chronic Kidney Disease Development in Patients Undergoing Nephrectomy for Renal Masses: A Pilot StudyJournal of Magnetic Resonance Imaging, 2026
- T1 Mapping of the Kidney2023
- Multiparametric Magnetic Resonance Investigations on Acute and Long‐Term Kidney InjuryJournal of Magnetic Resonance Imaging, 2023
- Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA‐targeted radioligand therapyThe Prostate, 2021
- The SNMMI and EANM practice guideline for renal scintigraphy in adultsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Nephrotoxicity after PRRT with 177Lu-DOTA-octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008